Viking Therapeutics stock faces dilution after USD 575.0 million raise

Published on 10/04/2026 at 17:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Viking Therapeutics stock closed at USD 29.94 on October 2, 2026, below the USD 35.00 offering price. VK2735 retained up to 97 percent of weight loss with less frequent dosing.

VKTX, US92686J1060, Illustration mit AI erstellt.

Viking Therapeutics (ISIN US92686J1060) closed at USD 29.94 on Nasdaq on October 2, 2026, down 1.87 percent for the session. The company closed a USD 575.0 million stock and convertible-note offering on September 28, 2026, putting financing and dilution alongside the latest VK2735 obesity data.

USD 575.0 million funds the pipeline

According to Viking Therapeutics on September 28, 2026, the financing included 9,035,714 common shares priced at USD 35.00 each and USD 258.75 million of 2.00 percent convertible senior notes due 2032.

The company estimated net proceeds of USD 547.8 million and said the funds would support VK2735, VK3019, research and development, working capital and general corporate purposes. At USD 29.94, the October 2 closing price stood 14.46 percent below the equity offering price, a gap that keeps the share issuance visible in the stock story.

VK2735 shows dosing flexibility

The financing followed September 22 maintenance results for VK2735. In the official release, Viking Therapeutics reported that every-other-week dosing maintained up to 97 percent of mean weight loss after the weekly induction phase, versus 61 percent for placebo.

Monthly dosing maintained up to 90 percent of mean weight loss against the same 61 percent placebo level. The study enrolled approximately 180 adults, used a 21-week induction period and added 12 weeks of maintenance dosing, while gastrointestinal adverse-event rates were similar to placebo during maintenance.

Analyst targets remain far above price

MarketBeat reported on October 4, 2026, that Truist Financial raised its target from USD 83.00 to USD 87.00 on September 23, while Oppenheimer set a USD 120.00 target on September 22. The same report listed a Moderate Buy consensus and an average target of USD 99.67 from 12 ratings firms.

The range of targets reflects the development-stage profile: the clinical data offer a dosing advantage, but Phase 3 execution and future commercialization still determine whether that advantage becomes a product opportunity. The October 2 close also remained within the 52-week range of USD 25.77 to USD 43.15.

Viking Therapeutics stock closes at USD 29.94

Viking Therapeutics stock closed at USD 29.94 on Nasdaq on October 2, 2026, with a market capitalization of USD 3.5 billion and volume of 6,332,241 shares. The next earnings report is scheduled for October 28, 2026.